Literature DB >> 18196261

Activity of neovascular lesions treated with bevacizumab: comparison between optical coherence tomography and fluorescein angiography.

Ilse Krebs1, Siamak Ansari-Shahrezaei, Alexandra Goll, Susanne Binder.   

Abstract

PURPOSE: To investigate whether examination with the non-invasive optical coherence tomography (OCT) alone is sufficient to ascertain the need of re-treatment with bevacizumab for exudative age-related macular degeneration (AMD) or the invasive fluorescein angiography (FA) is needed.
METHOD: Two independent examiners reviewed FA and OCT images and performed a semi-quantitative assessment from 0=no activity to activity 1-3, mild, moderate and advanced, respectively. Weighted Kappa indices were performed to calculate the concordance between OCT and FA.
RESULTS: A total of 153 OCT and FA examinations of 69 patients were evaluated, mean 2.2 examinations per patient. The mean age was 77.1+/-7.9 (55-89) years; 29.0% were male, 71.0% female. The weighted Kappa index showed concordance for activity in OCT and FA weak concerning the first investigation 4-6 weeks after initial treatment (0.3847) and obvious concerning the second investigation 8-10 weeks after initial treatment (0.4170). Higher values of activity were found with the OCT compared to FA. The most frequent reasons for discrepancies were detachment of the pigmentepithelium and fibrosis.
CONCLUSION: There is evidence of agreement between both examinations, the OCT was even more sensitive to detect activity of a lesion. In conducting studies based on OCT as single examination, it should be clearly defined how long fibrotic lesions or lesions with pigment epithelial detachment should be re-treated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18196261     DOI: 10.1007/s00417-007-0755-6

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  14 in total

1.  Optical coherence tomography guided retreatment of photodynamic therapy.

Authors:  I Krebs; S Binder; U Stolba; K Schmid; C Glittenberg; W Brannath; A Goll
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

2.  Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Macular Photocoagulation Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1991-09

3.  Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.

Authors:  Ziad F Bashshur; Ali Bazarbachi; Alexandre Schakal; Zeina A Haddad; Christelle P El Haibi; Baha' N Noureddin
Journal:  Am J Ophthalmol       Date:  2006-07       Impact factor: 5.258

4.  Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

Authors:  Ryan M Rich; Philip J Rosenfeld; Carmen A Puliafito; Sander R Dubovy; Janet L Davis; Harry W Flynn; Serafin Gonzalez; William J Feuer; Richard C Lin; Geeta A Lalwani; Jackie K Nguyen; Gaurav Kumar
Journal:  Retina       Date:  2006 May-Jun       Impact factor: 4.256

5.  Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study.

Authors:  Andrew A Moshfeghi; Philip J Rosenfeld; Carmen A Puliafito; Stephan Michels; Erin N Marcus; Joshua D Lenchus; Anna S Venkatraman
Journal:  Ophthalmology       Date:  2006-10-05       Impact factor: 12.079

6.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1999-10

Review 7.  Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update.

Authors: 
Journal:  Retina       Date:  2005 Feb-Mar       Impact factor: 4.256

8.  An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.

Authors:  Anne E Fung; Geeta A Lalwani; Philip J Rosenfeld; Sander R Dubovy; Stephan Michels; William J Feuer; Carmen A Puliafito; Janet L Davis; Harry W Flynn; Maria Esquiabro
Journal:  Am J Ophthalmol       Date:  2007-04       Impact factor: 5.258

9.  Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration.

Authors:  Pradeepa Yoganathan; Vincent A Deramo; James C Lai; Rajen K Tibrewala; David M Fastenberg
Journal:  Retina       Date:  2006 Nov-Dec       Impact factor: 4.256

10.  Agreement among ophthalmologists in evaluating fluorescein angiograms in patients with neovascular age-related macular degeneration for photodynamic therapy eligibility (FLAP-study).

Authors:  Frank G Holz; Jork Jorzik; Florian Schutt; Ulrike Flach; Kristina Unnebrink
Journal:  Ophthalmology       Date:  2003-02       Impact factor: 12.079

View more
  5 in total

1.  Confocal scanning laser ophthalmoscope in the retromode imaging modality in exudative age-related macular degeneration.

Authors:  Elisabetta Pilotto; Patrik Sportiello; Ernesto Alemany-Rubio; Stela Vujosevic; Sara Segalina; Iva Fregona; Edoardo Midena
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-04-29       Impact factor: 3.117

Review 2.  A comprehensive review of diagnostic imaging technologies to evaluate the retina and the optic disk.

Authors:  Asima Bajwa; Rabia Aman; Ashvini K Reddy
Journal:  Int Ophthalmol       Date:  2015-06-05       Impact factor: 2.031

3.  Cirrus OCT versus Spectralis OCT: differences in segmentation in fibrovascular pigment epithelial detachment.

Authors:  Eva Smretschnig; Ilse Krebs; Sarah Moussa; Siamak Ansari-Shahrezaei; Siamak Ansari-Shahrezarei; Susanne Binder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-05-23       Impact factor: 3.117

Review 4.  Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?

Authors:  Focke Ziemssen; Salvatore Grisanti; Karl Ulrich Bartz-Schmidt; Martin S Spitzer
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 5.  Clinical applications of optical coherence tomography in the posterior pole: the 2011 José Manuel Espino Lecture - Part II.

Authors:  J Fernando Arevalo; Andres F Lasave; Juan D Arias; Martin A Serrano; Fernando A Arevalo
Journal:  Clin Ophthalmol       Date:  2013-11-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.